广东光华科技股份有限公司 外汇衍生品交易业务管理制度 第一章 总则 第一条 为规范广东光华科技股份有限公司（以下简称"公司"）及所控制 下属各子公司的外汇衍生品交易业务，加强对外汇衍生品交易业务的管理，防范投 资风险，健全和完善公司外汇衍生品交易业务管理机制，确保公司资产安全，根据 《中华人民共和国公司法》、《中华人民共和国证券法》、《深圳证券交易所股票 上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》等法律、法规、规范性文件的有关规定及《公司章程》，结合公司实际情 况，制定本制度。 第二条 本制度所称外汇衍生品交易业务是指公司为满足正常生产经营需要， 在金融机构办理的规避和防范汇率风险的外汇衍生品交易业务。品种主要包括远 期结售汇、外汇期权、掉期等产品或上述产品的组合。 第三条 本制度适用于公司及所控制下属公司。公司所控制下属公司的外汇 衍生品交易业务由公司进行统一管理。 第二章 外汇衍生品交易业务的操作原则 第四条 公司进行外汇衍生品交易业务遵循合法、谨慎、安全和有效的原则， 严格控制外汇衍生品交易业务的交易种类及规模，以正常生产经营为基础，以具体 经营业务为依托，以 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 588,046,436.78, representing a 14.85% increase compared to CNY 512,003,803.74 in the same period last year[5] - Net profit attributable to shareholders reached CNY 25,213,223.30, a significant increase of 563.86% from CNY 3,797,978.50 year-on-year[5] - The net profit excluding non-recurring gains and losses was CNY 20,230,280.30, up 733.88% from CNY 2,426,056.50 in the previous year[5] - Basic and diluted earnings per share were both CNY 0.0542, reflecting a 470.53% increase from CNY 0.0095 in the same quarter last year[5] - The net profit for the period was CNY 25,184,258.65, a 595.44% increase from CNY 3,621,339.10 in the previous year, driven by revenue growth and improved gross margin[8] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 3,481,682,896.82, a decrease of 0.84% from CNY 3,511,244,173.09 at the end of the previous year[5] - Total assets amount to ¥3,481,682,896.82, down from ¥3,511,244,173.09, indicating a decrease of approximately 0.8%[14] - Current liabilities decreased to ¥1,447,380,422.72 from ¥1,463,266,378.64, a reduction of about 1.1%[14] - Long-term borrowings decreased to ¥112,472,000.00 from ¥149,976,000.00, a decline of approximately 25.0%[14] - The total liabilities amounted to ¥1,623,508,406.99, a decrease from ¥1,678,242,520.74[15] Cash Flow - The net cash flow from operating activities improved significantly to -CNY 2,730,238.76, a 95.71% increase compared to -CNY 63,607,947.05 in the previous year[5] - Cash flow from operating activities showed a net outflow of ¥2,730,238.76, an improvement from a net outflow of ¥63,607,947.05 in the previous period[18] - Net cash flow from investment activities was $84,791,168.87, compared to a negative cash flow of $22,301,997.48 in the previous period[19] - Total cash inflow from financing activities was $188,100,000.00, down from $210,985,000.00 in the prior period[19] - Net cash flow from financing activities improved to $33,679,290.84, compared to a negative cash flow of $2,057,881.22 previously[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 54,138[10] - The largest shareholder, Zheng Chuangfa, holds 22.08% of the shares, totaling 102,671,700 shares[10] - The number of shares held by the top 10 shareholders accounts for a significant portion of the company's equity, with the top three shareholders collectively holding over 32%[10] Operational Metrics - The company experienced a 40.83% increase in receivables financing, totaling CNY 77,347,850.33, indicating improved cash collection from customers[8] - The company's cash and cash equivalents increased to ¥761,006,302.94 from ¥639,245,044.34, representing a growth of approximately 19.0%[13] - Accounts receivable decreased to ¥577,368,265.30 from ¥654,720,771.23, a decline of about 11.8%[13] - Total operating revenue for the current period reached ¥588,046,436.78, an increase of 14.9% compared to ¥512,003,803.74 in the previous period[16] - Total operating costs increased to ¥592,053,743.15, up from ¥562,432,857.18, reflecting a rise of 5.5%[16] Comprehensive Income - The company reported a total comprehensive income of ¥25,172,837.48 for the current period, compared to ¥3,629,641.03 in the previous period[18] - Total equity attributable to shareholders increased to ¥1,857,592,613.14 from ¥1,832,390,811.01, reflecting a growth of 1.4%[15] Research and Development - Research and development expenses were ¥18,470,469.54, slightly down from ¥19,217,248.96, indicating a focus on cost management[16]

Financial Performance - The company reported a revenue of 1.2 billion RMB for the fiscal year 2024, representing a year-over-year increase of 15%[13]. - The company's operating revenue for 2024 was ¥2,589,007,825.65, a decrease of 4.09% compared to ¥2,699,461,878.86 in 2023[22]. - The net profit attributable to shareholders for 2024 was -¥204,947,173.80, showing an improvement of 52.42% from -¥430,712,868.12 in 2023[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥164,155,004.60 in 2024, a 62.02% improvement from -¥432,218,323.80 in 2023[22]. - The company reported a decrease in revenue after deducting certain amounts, with a net revenue of ¥2,579,485,110.30 in 2024 compared to ¥2,682,854,956.43 in 2023[23]. - The company achieved a revenue of 258,900.78 million yuan in 2024, a year-on-year decrease of 4.09%[51]. - The revenue from PCB chemicals reached 164,289.76 million yuan, representing a year-on-year growth of 20.23%[52]. - The lithium battery materials revenue declined by 55.25% to 26,089.18 million yuan[52]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2026[13]. - A strategic acquisition of a competitor is in progress, which is anticipated to enhance the company's production capacity by 30%[13]. - The company has shifted its business scope to include the production, research, and sales of lithium battery materials, as well as the development of chemical products[19]. - The company is focused on expanding its market presence through the production and sales of chemical raw materials and reagents, excluding hazardous and flammable materials[19]. - The company aims to enhance its independent innovation capabilities through the development of new products related to lithium iron phosphate and manganese iron lithium materials[71]. - The company plans to optimize its strategic layout in the new energy sector to enhance competitiveness amid cyclical fluctuations in the industry[65]. Research and Development - The company is investing 100 million RMB in R&D for new chemical reagents aimed at the electronics sector[13]. - The company is actively involved in the research and development of new technologies related to chemical products and lithium battery materials[19]. - The company holds 20 invention patents, 9 utility model patents, and 4 design patents, showcasing its commitment to innovation and technology leadership[43]. - The company has developed key production technologies, including multi-stage cooperative extraction and purification technology, solid product crystallization control technology, and chemical synthesis technology, enhancing its competitive edge in specialized chemicals[44]. - The company’s R&D investment continues to grow, with significant advancements in technology and product innovation in both PCB and new energy sectors[55]. Environmental Initiatives - Environmental initiatives have been implemented, reducing production waste by 40% over the past year[13]. - The company has completed environmental impact assessments for multiple projects, including a 36,000-ton lithium battery material project[156]. - The company has obtained a renewed pollution discharge permit valid until December 10, 2029[157]. - The total discharge of COD from the wastewater treatment plant was 25.02 tons, which is below the approved limit of 53.683 tons[158]. - The company operates two wastewater treatment facilities, ensuring compliance with stringent water quality standards[159]. - The company has implemented advanced pre-treatment processes to ensure that all discharge levels remain within regulatory limits[160]. Risk Management - Risks identified include intensified market competition and fluctuations in raw material prices, which may impact future performance[3]. - The company faces risks related to industry technology iteration, particularly in the lithium-ion battery cathode materials sector, which requires significant R&D investment and adaptation to market changes[100]. - The company emphasizes risk management by establishing a comprehensive risk management system to identify and respond to potential risks promptly[100]. - Safety production risks exist due to the hazardous nature of some raw materials, necessitating stringent safety management measures to prevent accidents[103]. Corporate Governance - The company maintains independence from its controlling shareholder, ensuring no non-operational fund transfers or interference in decision-making[109]. - The company has established a fair and transparent performance evaluation and incentive mechanism, linking the income of management and employees to business performance[110]. - The company has a complete financial department with independent accounting practices, ensuring compliance with accounting standards and regulations[113]. - The company actively communicates with investors, fostering a good interactive relationship and enhancing its image in the capital market[111]. Employee Development - The company has established a comprehensive training system covering various positions and growth stages to promote sustainable talent development[142]. - The total number of employees at the end of the reporting period is 1,213, with 876 from the parent company and 337 from major subsidiaries[139]. - The professional composition includes 442 production personnel, 91 sales personnel, 429 technical personnel, 32 financial personnel, and 219 administrative personnel, totaling 1,213[139]. Financial Management - The company plans to utilize up to ¥500 million of idle funds for cash management through low-risk financial products, with a maximum investment period of 12 months[87]. - The company has approved the use of ¥63,649,423.26 of raised funds to replace pre-invested self-raised funds for project financing[86]. - The company reported a significant increase in cash and cash equivalents, with a net increase of ¥334,980,753.39, compared to a decrease of ¥36,621,632.56 in the previous year, marking a 1,014.71% change[72]. Social Responsibility - The company actively supports social responsibility initiatives, including scholarships and talent development programs in collaboration with universities[57]. - The company participates in social welfare initiatives, including scholarships and support for sick children, earning recognition for its corporate social responsibility[175].

智通财经4月23日电，光华科技(002741.SZ)发布2025年第一季度报告，实现营业收入5.88亿元，同比增 长14.85%；归属于上市公司股东的净利润为2521.32万元，同比增长563.86%。 光华科技：一季度净利润同比增长564% ...

光华科技（002741）公告，2024年营业收入25.89亿元，同比下降4.09%。归属于上市公司股东的净亏损 2.05亿元，去年同期净亏损4.31亿元。基本每股收益-0.51元/股。公司计划不派发现金红利，不送红股， 不以公积金转增股本。 ...

光华科技（002741）公告，2025年第一季度营收为5.88亿元，同比增长14.85%；净利润为2521.32万 元，同比增长563.86%。 ...

Core Viewpoint - Guangdong Guanghua Technology Co., Ltd. has announced the change of its signing accountants, confirming the appointment of the new signing accountants for the 2024 annual audit [1]. Group 1: Announcement of Accountant Change - The company held meetings on April 26, 2024, and approved the proposal to reappoint Zhonghua Accounting Firm as the auditing institution for the 2024 fiscal year [1]. - The signing accountants have been changed from Wang Penglin and Xu Xirui to Kuai Yiyi and Xu Xirui, with the latter continuing to provide services for the annual audit [1]. Group 2: Information on New Signing Accountant - Kuai Yiyi has been engaged in auditing since 2005, with over 19 years of experience in securities services and has been a registered accountant since March 2008 [2]. - Kuai Yiyi has not faced any criminal penalties or administrative sanctions from regulatory bodies in the past three years [2]. - There are no independence issues concerning Kuai Yiyi as per the Code of Ethics for Chinese Certified Public Accountants [3]. Group 3: Transition and Impact - The transition of responsibilities during the change of signing accountants has been orderly, and it is stated that this change will not affect the audit of the company's 2024 annual financial statements and internal controls [4].

证券代码：002741 证券简称：光华科技 公告编号：2025-016 广东光华科技股份有限公司 关于变更签字会计师的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚 假记载、误导性陈述或重大遗漏。 广东光华科技股份有限公司（以下简称"公司"）2024 年 4 月 26 日召开第 五届董事会第十二次会议、第五届监事会第十一次会议审议通过了《关于续聘会 计师事务所的议案》，于 2024 年 5 月 17 日召开 2023 年年度股东大会，审议通 过了《关于续聘会计师事务所的议案》，同意公司续聘众华会计师事务所（特殊 普通合伙）（以下简称"众华所"）为公司 2024 年度审计机构。具体内容分别 详见公司 2024 年 4 月 27 日、2024 年 5 月 18 日在本公司指定信息披露网站巨潮 资讯网（www.cninfo.com.cn）刊登的《关于续聘会计师事务所的公告》。 公司于近日收到众华会计师事务所（特殊普通合伙）出具的《关于委派广东 光华科技股份有限公司签字注册会计师的说明函》，具体情况公告如下： 一、签字会计师变更情况 众华会计师事务所（特殊普通合伙）作为公司 2024 年年度 ...

证券代码：002741 证券简称：光华科技 公告编号：2025-015 广东光华科技股份有限公司 关于控股股东、实际控制人增持计划期限届满暨 实施完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、增持计划基本情况：广东光华科技股份有限公司（以下简称"公司"）于 2024 年 10 月 12 日披露了《关于控股股东、实际控制人增持公司股份计划的公 告》（公告编号：2024-030），控股股东、实际控制人郑靭先生（以下统称"增持 主体"）计划自 2024 年 10 月 14 日起 6 个月内，使用自有资金或自筹资金通过 深圳证券交易所交易系统允许的方式（包括但不限于集中竞价和大宗交易）增持 公司股票，本次增持不设增持股份价格的上限及下限，拟增持股数自 100 万股起。 2、目前增持计划实施期限届满，本次增持计划的实施期间，控股股东、实 际控制人郑靭先生通过深圳证券交易所交易系统集中竞价方式增持公司股份 100 万股，增持金额合计 1739.08 万元。 一、增持主体的基本情况 1、增持主体：公司控股股东、实际控制人、总经理郑靭先生。 2 ...

Group 1 - Company Instech reported a net profit of 177 million yuan for 2024, a year-on-year increase of 28.15%, with a proposed cash dividend of 1.20 yuan per 10 shares [1] - Instech achieved an operating revenue of 1.185 billion yuan in 2024, representing a year-on-year growth of 24.45% [1] - The company specializes in the research, production, and sales of rare earth permanent magnet materials and applications [2] Group 2 - Company Junda reported a net loss of 106 million yuan for Q1 2025, transitioning from profit to loss, with a year-on-year revenue decline of 49.52% [3] - Junda's operating revenue for Q1 2025 was 1.875 billion yuan [3] - The company focuses on the research, production, and sales of photovoltaic cell products [4] Group 3 - Company Annada reported a net loss of 10.26 million yuan for Q1 2025, with a year-on-year revenue increase of 1.44% [5] - Annada's operating revenue for Q1 2025 was 473 million yuan [5] - The company specializes in titanium dioxide and iron phosphate products [6] Group 4 - Company Jiuzhou Pharmaceutical reported a net profit of 250 million yuan for Q1 2025, a year-on-year increase of 5.68% [7] - Jiuzhou's operating revenue for Q1 2025 was 1.49 billion yuan, reflecting a year-on-year growth of 0.98% [7] - The company provides custom research and production services for pharmaceutical companies and research institutions [8] Group 5 - Company Yitong Century won a 1.48 billion yuan contract for a 5G comprehensive maintenance project with Guangdong Unicom [9] - The project will enhance the company's business volume and expansion in Guangdong [9] - Yitong Century specializes in communication network technology services and solutions [10] Group 6 - Company Rijiu Optoelectronics reported a net profit of 67.47 million yuan for 2024, a year-on-year increase of 506.9%, with a proposed cash dividend of 2.00 yuan per 10 shares [10] - Rijiu's operating revenue for 2024 was 583 million yuan, representing a year-on-year growth of 22% [10] - The company focuses on the research, production, and sales of touch display application materials [11] Group 7 - Company Ruotong reported a net profit of 95.98 million yuan for 2024, a year-on-year increase of 0.91%, with a proposed cash dividend of 2.00 yuan per 10 shares [12] - Ruotong's operating revenue for 2024 was 408 million yuan, reflecting a year-on-year growth of 7.54% [12] - The company specializes in drilling and completion equipment for oil and gas [13] Group 8 - Company Shuangxiang reported a net profit of 472 million yuan for 2024, a year-on-year increase of 754.84%, with a proposed cash dividend of 1.50 yuan per 10 shares [14] - Shuangxiang's operating revenue for 2024 was 2.29 billion yuan, representing a year-on-year growth of 51.55% [14] - The company focuses on synthetic leather and optical-grade PMMA products [15] Group 9 - Company Xinfang Pharmaceutical reported a net profit of 101 million yuan for 2024, a year-on-year decrease of 64.70%, with a proposed cash dividend of 0.30 yuan per 10 shares [16] - Xinfang's operating revenue for 2024 was 6.032 billion yuan, reflecting a year-on-year decline of 6.63% [16] - The company is involved in medical services, pharmaceutical distribution, and manufacturing [17] Group 10 - Company Dongxing Medical reported a net profit of 97.42 million yuan for 2024, a year-on-year increase of 0.21%, with a proposed cash dividend of 6.00 yuan per 10 shares [18] - Dongxing's operating revenue for 2024 was 435 million yuan, reflecting a year-on-year growth of 0.40% [18] - The company specializes in surgical medical devices [19] Group 11 - Company Wuzhou Special Paper reported a net profit of 64.68 million yuan for Q1 2025, a year-on-year decrease of 51.56%, with an operating revenue of 1.989 billion yuan [20] - Wuzhou's operating revenue for Q1 2025 increased by 15.21% [20] - The company focuses on the research, production, and sales of mechanism paper and pulp [21] Group 12 - Company Jinrui Mining expects a net profit of 15.28 million yuan for Q1 2025, a year-on-year increase of 617.40% [22] - The company specializes in the production and sales of strontium salt products [23] Group 13 - Company Youyan New Materials expects a net profit of 60 million to 75 million yuan for Q1 2025, a year-on-year increase of 13076% to 16370% [24] - The company focuses on electronic films, precious metal materials, and rare earth materials [25] Group 14 - Company Guoli expects a net profit of 11 million to 13 million yuan for Q1 2025, a year-on-year increase of 164.38% to 212.45% [26] - The company specializes in urban infrastructure design, construction, and investment [27] Group 15 - Company Shenzhen Airport reported a passenger throughput of 5.5422 million in March, a year-on-year increase of 8.70% [28] - The airport's cargo throughput was 171,900 tons, reflecting a year-on-year growth of 14.51% [28] - The company is involved in aviation and related non-aviation businesses [29] Group 16 - Company Shenghui Integration reported an order balance of 2.117 billion yuan as of March 31, 2025, a year-on-year increase of 11.89% [30] - The company provides cleanroom engineering and electromechanical engineering services [31] Group 17 - Company Chengyi Pharmaceutical received a drug registration certificate for Mercaptopurine tablets [32] - The drug is applicable for various diseases including choriocarcinoma and acute lymphoblastic leukemia [32] Group 18 - Company Enhua Pharmaceutical initiated Phase I clinical trials for NH280105 capsules, targeting Alzheimer's disease [33] - The trial aims to assess the safety and pharmacokinetics of the drug [33] Group 19 - Company Lingang Steel proposed a share buyback of 50 million to 100 million yuan [34] - The company specializes in the production and development of metallurgical products [35] Group 20 - Company Fujia plans to repurchase shares worth 15 million to 30 million yuan [36] - The company focuses on smart cleaning appliances and key components [37] Group 21 - Company Mould Technology received a project designation letter for exterior parts from a luxury car client, with an estimated total sales of 2.07 billion yuan [38] - The project is expected to start mass production in April 2027 [38] Group 22 - Company Longxin General expects a net profit of 4.55 billion to 5.30 billion yuan for Q1 2025, a year-on-year increase of 76.65% to 105.77% [39] - The company specializes in motorcycles, engines, and general machinery products [40] Group 23 - Company Dongfang Securities reported a net profit of 1.436 billion yuan for Q1 2025, a year-on-year increase of 62.08% [41] - The company focuses on investment management and securities trading [42] Group 24 - Company Yalian Machinery plans to use up to 800 million yuan of idle funds for low-risk financial products [43] - The company specializes in the production of engineered wood production lines and equipment [44] Group 25 - Company Guanghua Technology reported a net loss of 205 million yuan for 2024, with total revenue of 2.589 billion yuan [45] - The company focuses on PCB chemicals and lithium battery materials [46] Group 26 - Company Boya Biotechnology plans to publicly transfer 80% of its subsidiary's equity for 213 million yuan [47] - The transaction aims to optimize resource allocation focusing on blood products [48] Group 27 - Company Darui Electronics plans to repurchase shares worth 30 million to 50 million yuan [49] - The company specializes in customized components and automation equipment [50] Group 28 - Company Hongying Intelligent plans to repurchase shares worth 30 million to 40 million yuan [51] - The company focuses on smart control products and assemblies [52] Group 29 - Company Guangku Technology announced a change in the upper shareholding structure of its controlling shareholder [53] - The operational activities of the company will not be materially affected [54] Group 30 - Company Dingjie Smart's application for convertible bond issuance has been accepted by the Shenzhen Stock Exchange [55] - The company provides digital and intelligent solutions for various industries [56]